United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares of Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $515.03, for a total transaction of $4,892,785.00. Following the sale, the chief executive officer directly owned 324,443 shares of the company’s stock, valued at $167,097,878.29. This represents a 2.84% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

United Therapeutics Stock Performance

United Therapeutics stock opened at $501.27 on Friday. The firm has a market cap of $21.50 billion, a price-to-earnings ratio of 17.93, a PEG ratio of 1.73 and a beta of 0.59. United Therapeutics Corporation has a 52-week low of $302.19 and a 52-week high of $609.35. The firm has a 50 day moving average price of $536.95 and a two-hundred day moving average price of $535.97.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, beating analysts’ consensus estimates of $6.86 by $0.41. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The company had revenue of $783.30 million for the quarter, compared to analyst estimates of $804.65 million. During the same period in the prior year, the firm posted $6.41 EPS. The company’s quarterly revenue was down 1.9% on a year-over-year basis. As a group, equities research analysts predict that United Therapeutics Corporation will post 26.32 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have weighed in on UTHR. Wells Fargo & Company upgraded United Therapeutics from an “equal weight” rating to an “overweight” rating and increased their price target for the stock from $575.00 to $735.00 in a report on Thursday, May 7th. TD Cowen restated a “buy” rating on shares of United Therapeutics in a research report on Thursday, May 21st. Royal Bank Of Canada decreased their target price on United Therapeutics from $704.00 to $677.00 and set an “outperform” rating for the company in a research note on Thursday, August 6th. Weiss Ratings downgraded United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a report on Friday, July 31st. Finally, Bank of America dropped their price target on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a research note on Friday, July 10th. Eleven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, United Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $646.00.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Torren Management LLC bought a new position in United Therapeutics in the 4th quarter valued at about $26,000. Activest Wealth Management increased its holdings in United Therapeutics by 1,400.0% during the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 56 shares in the last quarter. WealthCollab LLC increased its holdings in United Therapeutics by 55.9% during the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 38 shares in the last quarter. Rakuten Securities Inc. raised its stake in shares of United Therapeutics by 76.7% in the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 46 shares during the last quarter. Finally, Entrust Financial LLC purchased a new stake in shares of United Therapeutics in the fourth quarter worth approximately $31,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.